OBJECTIVE: To assess the clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma (DLBCL). METHODS: A retrospective study of 37 patients with primary testicular DLBCL was carried out from November 2003 to May 2012. Their clinical features, survival and prognostic factors were analyzed. RESULTS: During a median follow-up period of 39.8 months (5.4-93.0 months), the median progression-free survival (PFS) was 26.2 months (95% CI: 0-65 months) and the 3-year overall survival (OS) rate was 78.4%. Within the whole cohort, the factors significantly associated with a superior PFS were limited stage (stage I/II), lactate dehydrogenase (LDH) ≤245 U/L, international prognostic index (IPI) ≤1, primary tumor diameter <7.5 cm, and patients who had complete response (CR) and received doxorubicin-contained chemotherapy (P<0.05). There was a trend toward superior outcome for patients who received combined therapy (surgery/chemotherapy/radiotherapy) (P=0.055). Patients who had CR, primary tumor diameter <7.5 cm and IPI score ≤1 were significantly associated with longer PFS at multivariate analysis. CONCLUSIONS: Primary testicular DLBCL had poorer survival. CR, primary tumor diameter and IPI were independent prognostic factors. The combined therapy of orchectomy, doxorubicin-contained chemotherapy and contralateral testicular radiotherapy (RT) seemed to improve survival.
OBJECTIVE: To assess the clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma (DLBCL). METHODS: A retrospective study of 37 patients with primary testicular DLBCL was carried out from November 2003 to May 2012. Their clinical features, survival and prognostic factors were analyzed. RESULTS: During a median follow-up period of 39.8 months (5.4-93.0 months), the median progression-free survival (PFS) was 26.2 months (95% CI: 0-65 months) and the 3-year overall survival (OS) rate was 78.4%. Within the whole cohort, the factors significantly associated with a superior PFS were limited stage (stage I/II), lactate dehydrogenase (LDH) ≤245 U/L, international prognostic index (IPI) ≤1, primary tumor diameter <7.5 cm, and patients who had complete response (CR) and received doxorubicin-contained chemotherapy (P<0.05). There was a trend toward superior outcome for patients who received combined therapy (surgery/chemotherapy/radiotherapy) (P=0.055). Patients who had CR, primary tumor diameter <7.5 cm and IPI score ≤1 were significantly associated with longer PFS at multivariate analysis. CONCLUSIONS: Primary testicular DLBCL had poorer survival. CR, primary tumor diameter and IPI were independent prognostic factors. The combined therapy of orchectomy, doxorubicin-contained chemotherapy and contralateral testicular radiotherapy (RT) seemed to improve survival.
Authors: D Pectasides; T Economopoulos; G Kouvatseas; A Antoniou; Z Zoumbos; G Aravantinos; C Tsatalas; A Halikia; C Nikolaides; C Kiamouris; E Pappa; N Pavlidis; D Skarlos; G Fountzilas; M A Dimopoulos Journal: Oncology Date: 2000-05 Impact factor: 2.935
Authors: R Fonseca; T M Habermann; J P Colgan; B P O'Neill; W L White; T E Witzig; K S Egan; J A Martenson; L J Burgart; D J Inwards Journal: Cancer Date: 2000-01-01 Impact factor: 6.860
Authors: Laurie H Sehn; Jane Donaldson; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Richard Klasa; Nicol MacPherson; Susan O'Reilly; John J Spinelli; Judy Sutherland; Kenneth S Wilson; Randy D Gascoyne; Joseph M Connors Journal: J Clin Oncol Date: 2005-06-13 Impact factor: 44.544
Authors: C Tondini; A J Ferreri; L Siracusano; P Valagussa; R Giardini; I Rampinelli; G Bonadonna Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan Journal: Blood Date: 2003-09-22 Impact factor: 22.113
Authors: E Zucca; A Conconi; T I Mughal; A H Sarris; J F Seymour; U Vitolo; R Klasa; M Ozsahin; G M Mead; M A Gianni; S Cortelazzo; A J M Ferreri; A Ambrosetti; M Martelli; C Thiéblemont; H Gomez Moreno; G Pinotti; G Martinelli; R Mozzana; S Grisanti; M Provencio; M Balzarotti; F Laveder; G Oltean; V Callea; P Roy; F Cavalli; M K Gospodarowicz Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544